Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for...

Prof Anthony Moorman - Newcastle University, Newcastle upon Tyne, UK

UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion ( Prof Anthony Moorman - Newcastle University, Newcastle upon Tyne, UK )

Long-term disease control in multiple myeloma by in-class transitioning: A...

Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA

Long-term disease control in multiple myeloma by in-class transitioning: A community-based study ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )

Treating acute lymphoblastic leukaemia in the era of COVID-19

Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Treating acute lymphoblastic leukaemia in the era of COVID-19 ( Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA )

Managing acute myeloid leukaemia during the COVID-19 pandemic

Dr Naval Daver - MD Anderson Cancer Center, Houston, USA

Managing acute myeloid leukaemia during the COVID-19 pandemic ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )

Gut microbiome disturbance by antibiotic treatment early in life is sufficient...

Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca...

Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice ( Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca, Salamanca, Spain )

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with...

Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA

$Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )$

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat...

Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma ( Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy )

Treating patients with multiple myeloma in the real world

Dr Ajai Chari and Prof Roman Hájek

Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or...

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma

Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain

KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients...

Dr Naval Daver - MD Anderson Cancer Center, Houston, USA

Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )

More from ecancer